logo-loader

Moleculin Biotech shares rocket as it becomes 'clinical-stage' group after FDA decision

Last updated: 11:16 26 Sep 2017 EDT, First published: 03:16 26 Sep 2017 EDT

1506428418_shutterstock_313800692
Pictured are cancer cells

Shares in Moleculin Biotech Inc (NASDAQ:MBRX) shot up over 34% in pre-market deals as it received welcome FDA news.

The Food and Drug Administration (FDA) has authorised the group to begin clinical trials of  candidate Annamycin for relapsed or refractory Acute Myeloid Leukemia (AML).

It came after the FDA completed its safety review of information and a proposed protocol submitted by Moleculin in an Investigational New Drug application (IND).

"This represents a tremendous milestone for Moleculin," said Walter Klemp, chairman and chief executive at Moleculin.

"Our primary focus has been to get Annamycin back into the clinic so we can begin optimizing the dosing of the drug as the next step in evaluating its potential to become the first 2nd line therapy suitable for the majority of relapsed or refractory AML patients. It is a thrill to now refer to Moleculin as a 'clinical stage' company."

Annamycin is the group's lead candidate. It also has two preclinical small molecule portfolios in development, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

1 hour, 52 minutes ago